Evidence for a regulated Ca\(^{2+}\) entry in proximal tubular cells and its implication in calcium stone formation

Cliff-Lawrence Ibeh\(^1\), Allen J. Yiu\(^1\,2\), Yianni L. Kanaras\(^1\), Edina Paal\(^3\), Lutz Birnbaumer\(^4\,5\), Pedro A. Jose\(^2\,6\) and Bidhan C. Bandyopadhyay\(^1\,2\,6\,\ast\)

ABSTRACT

Calcium phosphate (CaP) crystals, which begin to form in the early segments of the loop of Henle (LOH), are known to act as precursors for calcium stone formation. The proximal tubule (PT), which is just upstream of the LOH and is a major site for Ca\(^{2+}\) reabsorption, could be a regulator of such CaP crystal formation. However, PT Ca\(^{2+}\) reabsorption is mostly described as being paracellular. Here, we show the existence of a regulated transcellular Ca\(^{2+}\) entry pathway in luminal membrane PT cells induced by Ca\(^{2+}\)-sensing receptor (CSR, also known as CASR)-mediated activation of transient receptor potential canonical 3 (TRPC3) channels. In support of this idea, we found that both CSR and TRPC3 are physically and functionally coupled at the luminal membrane of PT cells. More importantly, TRPC3-deficient mice presented with a deficiency in urinary Ca\(^{2+}\) (Friedman, 2000) and thus is critical in the prevention of urinary Ca\(^{2+}\) supersaturation. Such regulation of Ca\(^{2+}\) homeostasis, via Ca\(^{2+}\) entry, takes place throughout the nephron (Hoenderop et al., 2005), for example, in the proximal tubule (PT), thick ascending limb (TAL) of the loop of Henle (LOH), and the distal convoluted tubule (DCT), of which the PT accounts for \(\sim 70\%\) of Ca\(^{2+}\) reabsorbed by the kidney (Friedman and Gesek, 1995; Ng et al., 1984). Studies have demonstrated the role of paracellular pathway in the movements of Ca\(^{2+}\) through the tight junctions, which occurs in the PT and TAL, whereas the transcellular pathway, which involves the movement of Ca\(^{2+}\) across the epithelia, is known to take place in DCT (Thongon et al., 2008). The paracellular pathway efficiently transports the bulk of Ca\(^{2+}\) through the tight junctions, whereas the transcellular route involves transporting Ca\(^{2+}\) for fine-tuning and could be important in preventing Ca\(^{2+}\) deposition in the parts of nephron distal to the PT, such as the LOH (Evans et al., 2003). Considerable reabsorption of Ca\(^{2+}\) occurs in the PT through the paracellular pathway, which is not regulated by hormones or drugs, whereas the mechanism of transcellular Ca\(^{2+}\) transport is unclear. Although the amount of active transport via a transcellular pathway (Ulrich et al., 1976; White et al., 1997) in the PT is small, it is twice that of the DCT where Ca\(^{2+}\) reabsorption is entirely transcellular, and is mediated by Ca\(^{2+}\)-sensing receptor (CSR, also known as CASR)-induced Ca\(^{2+}\) entry through transient receptor potential (TRP) vanilloid (V) 5 and 6 (TRPV5 and TRPV6), Ca\(^{2+}\)-selective channels at the luminal membrane (Lambers et al., 2006). Surprisingly, epithelial Ca\(^{2+}\) transporting channels such as TRPV5 and TRPV6 are not found in the PT (den Dekker et al., 2003). Interestingly, CSR is also prominently expressed at the apical (brush border) membrane in the PT, whereas in the cortical TAL, the CSR is located mostly at the basolateral membrane to regulate the Ca\(^{2+}\) level independently of parathyroid hormone (PTH; Louny et al., 2012). Therefore, the CSR in PT cells can activate apical Ca\(^{2+}\) influx to maintain the Ca\(^{2+}\) level in PT luminal fluid to prevent any downstream Ca\(^{2+}\) supersaturation in the LOH (Aspin et al., 1996), which could initiate calcium phosphate (CaP) crystal formation leading to calcium stone formation. The CSR, a member of subfamily 3 (or C) of G-protein coupled receptors (GPCR; Brown et al., 1993), is expressed in a wide variety of epithelial tissues, including the parathyroid gland, kidney and gastrointestinal tract and plays a key role in the homeostasis of extracellular Ca\(^{2+}\) ([Ca\(^{2+}\)]\textsubscript{e}), mainly through the activation of the phospholipase C\(\beta\) (PL\(\beta\)) pathway (Chang et al., 2000). CSR activation stimulates the PLC\(\beta\) enzyme to cleave phosphatidylinositol-4, 5-biphosphate (PIP\(_2\)) into diacylglycerol (DAG) and inositol triphosphate (IP\(_3\)), which then causes a further increase in intracellular calcium ([Ca\(^{2+}\)]\textsubscript{i}) through Ca\(^{2+}\) entry (Werry et al., 2003) by activating TRPC channels (TRPC1, TRPC2, TRPC4 and TRPC5; Bergdahl et al., 2005; Vazquez et al., 2004; Vennekens et al., 2002). DAG also triggers Ca\(^{2+}\) influx across the plasma membrane by directly activating TRPC3, TRPC6 and TRPC7 channels (Dietrich et al., 2005; Hofmann et al., 1999; Venkatachalap et al., 2003), further elevating [Ca\(^{2+}\)]\textsubscript{i}. We have reported that the increase in [Ca\(^{2+}\)]\textsubscript{i}, allows for the formation of a functional TRPC–Ca\(^{2+}\) signaling complex that mediates transcellular Ca\(^{2+}\) transport via a TRPC3–TRPC6 channels.
in a renal collecting duct (CD) cell line (Bandyopadhyay et al., 2005), which was further confirmed in rat CD cells (Goel et al., 2007).

While transcellular Ca\(^{2+}\) transport in PT cells remains elusive, we found that CSR can activate TRPC3-mediated Ca\(^{2+}\) entry, causing transepithelial Ca\(^{2+}\) flux in mice salivary duct (i.e. an ion-transporting epithelia) (Bandyopadhyay et al., 2012), suggesting that TRPC3 in PT is in a position to mediate transcellular Ca\(^{2+}\) flux (Goel and Schilling, 2010). Here, we show that CSR in the apical membrane of murine renal PT cells can indeed activate TRPC3, triggering Ca\(^{2+}\) entry and leading to transepithelial Ca\(^{2+}\) flux across the PT cell. More importantly, pharmacological inhibition of both CSR and TRPC3 and genetic disruption of TRPC3 markedly attenuated such Ca\(^{2+}\) influx in PT cells. Finally, TRPC3-knockout (KO) mice displayed a phenotype of elevated urinary [Ca\(^{2+}\)] and the presence of CaP crystals in LOH. Since the nucleation of such CaP crystals act as a precursor for CaP and calcium oxalate (CaOx) mixed crystal formation, this discovery is a significant step towards understanding the mechanism of calcium nephrolithiasis, which accounts for majority (70–80%) of all renal stones.

**RESULTS**

**TRPC3 as a Ca\(^{2+}\)-entry channel in LLC-PK1 cells**

We have recently demonstrated a CSR-dependent TRPC-like Ca\(^{2+}\) current in LLC-PK1 cells regulated by a PLC\(\beta\)-dependent signaling pathway (Yiu et al., 2017). Porcine-derived LLC-PK1 cells exhibit some key features of PT epithelia (Brismar et al., 1998). Thus, to delineate the mechanism of CSR-induced Ca\(^{2+}\) entry in these cells, we explored a similar mechanism related to our finding in salivary ductal epithelia (Bandyopadhyay et al., 2012). Our data show that TRPC3, a Ca\(^{2+}\) permeable channel, is expressed in LLC-PK1 cells (Fig. 1A), more importantly, in the apical membrane (Fig. 1B). Accordingly, to examine the role of TRPC3 in LLC-PK1 cells, we measured [Ca\(^{2+}\)] in these cells to determine the Ca\(^{2+}\) mobilization in response to CSR and TRPC3. Our data show that CSR activation mediated by the endogenous allosteric activator L-phenylalanine (L-Phe), caused a pronounced increase in [Ca\(^{2+}\)] in these LLC-PK1 cells, which was inhibited by the allosteric CSR-inhibitor NPS-2143 (NPS; 1 \(\mu\)M), the TRPC channel blocker SKF-96365 (SKF; 1 \(\mu\)M) and the TRPC3 inhibitor (Pyr3; 3 \(\mu\)M). The bar diagram in the inset shows the peak Ca\(^{2+}\) response corresponding to the each Ca\(^{2+}\) transient expressed as the fluorescence ratio \(\frac{F_{340/380}}{}\) for each treatment condition (assigned colors mentioned in the figure) of the cells. The blue boxes above traces display the Ca\(^{2+}\)\(^\text{c}\) conditions. (D) The TRPC3 activator (OAG; 100 \(\mu\)M)-stimulated membrane current is blocked by Pyr (3 \(\mu\)M) in LLC-PK1 cells. (E) A current–voltage (\(I\)–\(V\)) relationship plot shows the OAG-induced outwardly rectified TRPC3 (blocked by Pyr; 3 \(\mu\)M) current obtained by ramping from \(-100\) to \(+100\) mV. (F) Bars represent the average data (from experiments as in D) normalized to current densities. Results represent means\(\pm\)s.e.m. from \(n=4\) experiments. \(*P<0.05; \**P<0.01\) (one-way ANOVA with post-hoc Tukey for C and F). Scale bars: 40 \(\mu\)m.
increase in $[\text{Ca}^{2+}]_i$ is a result of $\text{Ca}^{2+}$ influx via TRPC channel(s). Similarly, we observed reduction in $\text{Ca}^{2+}$ mobilization when using the TRPC3 inhibitor Pyr3 (Kiyonaka et al., 2009), suggesting the presence of a CSR–TRPC3 signaling pathway in these cells. To confirm the direct activation of TRPC3, the cell-permeable DAG analog 1-oleoyl-2-acetyl-sn-glycerol (OAG) was applied, generating an outwardly rectified membrane current (Fig. 1D–F), which is significantly blocked by Pyr3. These data show that CSR–TRPC3 signaling occurs in LLC-PK1 cells, which may have a role in transcellular $\text{Ca}^{2+}$ transport.

**Ca$^{2+}$-sensing in PT cells**

GPCR(s) that are linked to PLC, such as CSR, are expressed in a wide variety of epithelial tissues, including renal tubular epithelial cells, and play a key role in regulating $[\text{Ca}^{2+}]_o$, mainly through $\text{Ca}^{2+}$ entry channel activation via the PLC pathway (Chow et al., 2011). Thus, to understand to what extent such a process is present in innate PT cells, we looked for $[\text{Ca}^{2+}]_o$-induced $\text{Ca}^{2+}$ entry as a functional response of CSR in murine PT cells. Our results show a $[\text{Ca}^{2+}]_o$-induced rise in $[\text{Ca}^{2+}]_i$ in these cells that is blocked upon addition of extracellular EGTA (a $\text{Ca}^{2+}$ chelator; Fig. 2A), indicating that there is a $[\text{Ca}^{2+}]_o$-dependent response in PT cells. The purity of our isolated PT cells from wild-type (WT) mice was verified by RT-PCR to confirm the presence of the mRNAs encoding PT markers (Fig. S1A,B; Table S1), such as megalin and CD13B, and the absence of those encoding aquaporin 2 (distal tubule and CD marker), $\text{Cl}^-/\text{HCO}_3^-$-anion exchanger (AE-1; for intercalated CD cells), podocin (glomerular epithelial cell) and $\alpha$-smooth muscle actin (SMA, blood vessels). To provide functional evidence that we had isolated PT cells, we measured single-cell $[\text{Ca}^{2+}]_i$ transients in dispersed/cultured PT cells loaded with Fura-2-AM (a $\text{Ca}^{2+}$ probe; 5–8 µM), using the ratiometric method, as described previously ([[Ca]$_i$], was measured as the ratio of fluorescence emission at 510 nm following excitation at 340 and 380 nm (F$_{340/380}$) (Bandyopadhyay et al., 2012; Yiu et al., 2017). An angiotensin II (10$^{-7}$ M)-induced $[\text{Ca}^{2+}]_i$ increase and its block by 10 µM losartan (Fig. S1C) was used as a control for a positive functional $\text{Ca}^{2+}$ response in these PT cells (Zhuo et al., 2006). Moreover, inhibition of the angiotensin II-evoked $\text{Ca}^{2+}$ current by losartan was confirmed as a positive functional signature for the PT cells (Fig. S1D).

![Fig. 2. CSR mediates $\text{Ca}^{2+}$ flux in PT cells.](image-url)
Next, we looked for the presence of CSR in mice kidney tissue and found that CSR is expressed in both renal cortex and medulla (Fig. 2B), which was then confirmed by both immunofluorescence (Fig. 2C) and immunocytochemistry (Fig. S2A) analyses using a specific antibody to CSR. We found that CSR is predominantly present at the luminal brush border (Fig. 2C) of PT cells, at both the proximal convoluted tubule (PCT) and proximal straight tubule (PST; Fig. S2B). We assessed CSR activity in PT cells by analyzing the rise in [Ca²⁺], in response to increasing concentrations of [Ca²⁺]₀ (0.5–12 mM), which was largely inhibited by NPS-2143 (Fig. 2D). Several conventional agonists of CSR, such as neomycin and Gd³⁺ (50–200 μM; Fig. 2E,F), elicited increases in [Ca²⁺], supporting the concept of CSR activity. The Gd³⁺ response was blocked by treatment with the PLC inhibitor U-73122 (500 μM), indicating that CSR in PT cells stimulates PLC activity (Fig. 2E), which also supports the PLC pathway in PT cells (Mogami et al., 1997). We further confirmed the specificity of the anti-TRPC3 antibody by coimmunoprecipitation (co-IP). Our results show that co-IP of CSR and TRPC3 complex forms only in the PT (Fig. S3A, B; den Dekker et al., 2003). Since our data show that TRPC3 could mediate Ca²⁺ entry in LLC-PK1 cells, we performed RT-PCR and confirmed that the gene is expressed only in renal PT (Fig. S3C–D). We searched for a mechanism in PT similar to the process of [Ca²⁺] transport in the DCT, which occurs via TRPV5 and TRPV6. Such a mechanism in the PT could play a significant role in maintaining the [Ca²⁺] in parts of the nephron distal to the PT (Lassiter et al., 1963). Interestingly, we found that CSR regulates TRPC3 in salivary duct through their mutual interaction (Bandopadhyay et al., 2012). Therefore, we performed immunofluorescence labeling in mice kidney sections and found that TRPC3 and CSR are both apically localized in PT cells (Fig. 4A), with a significant amount of colocalization (the Manders’ colocalization coefficient value was 0.902 and weighted colocalization coefficient was 0.942) at the luminal region of the PT cells (Fig. 4B). To support our colocalization, we used kidney cortical tissue from rats to determine apical and basolateral complex formation by coimmunoprecipitation (co-IP). Our results show that co-IP of CSR and TRPC3 occurred only in the PT apical membrane fraction (Fig. S5B,C), suggesting the CSR and TRPC3 complex forms only at the apical membrane of kidney cortex (mostly containing PT cells). These data thus support an apical CSR–TRPC3 signaling in PT cells that could have an instrumental role in transcellular Ca²⁺ transport to regulate PT luminal fluid [Ca²⁺]. Ca²⁺ entry through TRPC3 can be modulated by endogenous CSR modulators such as the aromatic amino acids L-Phe and L-tryptophan (L-Trp), which are present in large amounts in the PT luminal fluid (Conigrave and Lok, 2004). Therefore, we tested the functional interaction between CSR and TRPC3 after treatment with L-Phe and L-Trp, in a minimal Ca²⁺ medium (0.5 mM). Our data show both amino acids induced a small Ca²⁺ release followed by a pronounced Ca²⁺ entry, which was blocked by NPS-2143 (1 μM; Fig. 4C), suggesting the existence of CSR-mediated Ca²⁺ transport in PT cells.

Next, to substantiate the above findings, we performed electrophysiology in PT cells to confirm CSR-induced current activation. Our data show that treatment with L-Phe (10 mM) with minimal (0.5 mM) external [Ca²⁺], can induce a membrane current, which was inactivated quickly and efficiently by the CSR blocker (Fig. 4D) NPS-2143. Consistent with our previous report (Yiu et al., 2017), the I–V relationship was linear, showing an outwardly rectified non-selective cation current with a reversal potential near 0 mV, typical for TRPC channels (Fig. 4E). Therefore, we performed electrophysiology and Ca²⁺ imaging experiments to determine whether such a non-selective cation current is due to the activation of TRPC channels. Application of SKF-96365 reduced L-Phe-stimulated Ca²⁺ entry (Fig. 4F) and current (Fig. 4G) in PT cells, indicating a CSR-induced TRPC current innate to PT cells. GPCR (CSR)-induced activation of TRPC3 can generate both ER Ca²⁺ store release due to IP3 generation, known as store-operated Ca²⁺ entry (SOCE) and a direct activation via DAG, called receptor-operated Ca²⁺ entry (ROCE). Thus, to distinguish between TRPC3

**Evidence for a regulated Ca²⁺ entry pathway in PT cells via TRPC3**

CSR plays a key role in [Ca²⁺] transport, mainly through TRPV5 and TRPV6 (Topala et al., 2009) in the DCT, which is responsible for only 10–15% of reabsorption of the filtered Ca²⁺ (Costanzo and Windhager, 1978). By contrast, the 65–70% Ca²⁺ transport by the PT could play the primary role in maintaining the [Ca²⁺] in parts of the nephron distal to the PT (Lassiter et al., 1963). However, a major obstacle in understanding the role of any regulated Ca²⁺ transport by PT cells is the lack of a description of an apical Ca²⁺-transporting channel as the epithelial Ca²⁺ absorptive channel; TRPV5 and TRPV6 are not present in the PT (Fig. S3A, B; den Dekker et al., 2003). Since our data show that TRPC3 could mediate Ca²⁺ entry in LLC-PK1 cells, we performed RT-PCR and confirmed that the Trpc3 gene is expressed in murine PT cells and in WT kidneys (Fig. S3A–C). Indeed, we found that TRPC3 protein is expressed only in renal cortex (Fig. 3A) and specifically localized to the apical membrane of the PT (Fig. 3B), at both the PCT and PST (Fig. S4A–D). We further confirmed the specificity of the anti-TRPC3 antibody by analyzing kidney sections from WT and TRPC3 KO mice (Fig. S4E–H). We tested the spatial function of the CSR-stimulated TRPC3 response, and found that L-Phe caused a prolonged increased in apical [Ca²⁺] to a greater extent than at the basolateral surface (Fig. 3C). More importantly, OAG (100 μM) directly activated TRPC3 induced a Ca²⁺ entry, which is limited to the apical region in these PT cells (Bandopadhyay et al., 2005), and this effect was almost completely blocked by the apical application of the TRPC3 blocker Pyr3 (Fig. 3D), thus validating the rectified non-selective cation current with a reversal potential near 0 mV, typical for TRPC channels (Fig. 4E). Therefore, we performed electrophysiology and Ca²⁺ imaging experiments to determine whether such a non-selective cation current is due to the activation of TRPC channels. Application of SKF-96365 reduced L-Phe-stimulated Ca²⁺ entry (Fig. 4F) and current (Fig. 4G) in PT cells, indicating a CSR-induced TRPC current innate to PT cells. GPCR (CSR)-induced activation of TRPC3 can generate both ER Ca²⁺ store release due to IP₃ generation, known as store-operated Ca²⁺ entry (SOCE) and a direct activation via DAG, called receptor-operated Ca²⁺ entry (ROCE). Thus, to distinguish between TRPC3
ROCE and SOCE, we used Pyr6 and Pyr10, since Pyr3 is equally potent for ROCE and SOCE inhibition (Schleifer et al., 2012). Our data show that Pyr10 has a greater blocking effect for the Ca^{2+} entry response (Fig. 4H), suggesting that CSR-mediated activation of TRPC3 is mainly due to direct activation pathway and could be the major mechanism mediating Ca^{2+} influx in PT cells. In contrast, Pyr6 and Pyr3 shows a less potent block than Pyr10, which suggests that SOCE, which can involve other players of this pathway, plays a lesser role, which further suggests that CSR-mediated activation of TRPC3 via ROCE is the main Ca^{2+} entry pathway in PT cells (Schleifer et al., 2012).

CSR activation promotes TRPC3 function expression in PT cells

We previously reported that TRPC3 forms a signaling complex with key Ca^{2+} signaling proteins to mediate dynamic CSR–TRPC3 interactions to regulate TRPC3 function (Bandyopadhyay et al., 2005, 2012). Thus, we performed co-IP experiments using PT cell lysates to establish whether CSR is a signaling partner of TRPC3. Our co-IP experiments using anti-TRPC3 and -CSR antibodies showed that TRPC3 and CSR physically interact with each other in the kidney, and more so in the cortex (Fig. 5A,B) than in the medulla. These data, and the data showing that the CSR effect of L-Phe can be blocked by SKF-96365 and Pyr3 (Fig. 4D–H), suggest that CSR is an upstream signaling partner of TRPC3 and activates Ca^{2+} entry through TRPC3 via a PLC-dependent mechanism (Fig. 2E) in the PT S1 and S2 segments in cortical nephrons. Hence, we prove that CSR and TRPC3 can form a functional complex in PT cells, similar to what we found in other ion-transporting epithelia (Bandyopadhyay et al., 2012).

Since we have demonstrated for the first time that TRPC3 can form an apical Ca^{2+} signaling complex, acting as a Ca^{2+}-permeating or entry channel in kidney epithelia (Bandyopadhyay et al., 2005), we performed co-IP experiments examining the effect of CSR activation induced by L-Phe. Our data in Fig. 5C show that incubation of PT cells with L-Phe and Ca^{2+} caused a marked increase in the CSR–TRPC3 complex formation in these cells. We have shown previously that GPCR-stimulated plasma membrane (PM) expression of TRPC3 is required for a functional TRPC3 channel (Singh et al., 2004). We, therefore, determined whether CSR can regulate surface (PM)
Fig. 4. Colocalization and function interaction of TRPC3 and CSR in PT cells. (A) Images show immunofluorescence staining of CSR (red) and TRPC3 (green) in a mouse kidney section. Arrows indicate CSR (white) and TRPC3 (yellow) stained at the apical region; in the overlay, blue arrows indicate the colocalization (yellow). (B) Colocalization analysis of CSR and TRPC3 in PT cells validated by calculating overlapping index (>75%) using Zen 2010 image analysis software. (C) Ca²⁺-imaging traces of PT cells bathed in 0.5 mM Ca²⁺, then with Ca²⁺ (2.5 mM) added (as shown in the blue boxes). Activation of CSR by aromatic amino acids L-Phe (10 mM) and L-Trp (12 mM) induced Ca²⁺ entry. Ca²⁺ entry was blocked by NPS-2143 (NPS, 1 µM). (D,E) Whole-cell patch clamp measurements of mouse PT cells in presence of extracellular solution containing 10 mM L-Phe and 1.2 mM Ca²⁺. Graphical plots of average data represented as a timecourse, showing currents at +100 mV after exposure to (D) L-Phe and NPS-2143 (1 µM), and (E) the average basal, L-Phe-induced and L-Phe+NPS-2143 currents (inset) plotted with an I–V relationship plot showing an outwardly rectified current ramping from −100 to +100 mV. (F) Ca²⁺ imaging traces of PT cells showing the response to activation of CSR by L-Phe (control) 10 mM) and blockade by SKF-96365 (SKF, 1 µM). The graph in the inset shows comparison between the peak Ca²⁺ entries among the control, Pyr3, Pyr6 and Pyr10. Results represent means±s.e.m. from n=4 experiments. *P<0.05; **P<0.01 (unpaired two-tailed t-test for F, and one-way ANOVA with a post-hoc Tukey test for G and H). Scale bars: 20 µm.
expression of TRPC3 in PT cells. We performed surface biotinylation experiments using polarized PT cells to test whether the stimulation of CSR can stimulate the insertion of TRPC3 into the PM of PT cells. Our data show that apical application of L-Phe (10 mM+2 mM Ca2+) for 1, 3 and 5 min duration caused a time-dependent increase of TRPC3 in the biotinylated fraction (Fig. 5D; Fig. S5D–F), suggesting that CSR activation-induced TRPC3 PM insertion was time dependent (peaked at 3 min). By contrast, another PM protein, the amount of Na+/K+-ATPase, did not change in those biotinylated fractions (Fig. 5D), demonstrating the specificity of the process. Taken together, these data suggest that L-Phe present in PT luminal fluid could be a regulator of TRPC3 PM expression and function in PT cells. We (Bandyopadhyay et al., 2012), and others (Feng et al., 2011) have previously shown such linkage; however, the existence of such association in PT cells had not been reported before. We propose that disruption of such Ca2+ signaling in PT cells can result in compromised TRPC3 function and could lead to Ca2+ supersaturation in the PT.

**TRPC3 KO mice have a reduction of CSR-induced Ca2+ entry in PT cells**

We used TRPC3 KO mice as a genetic model, and confirmed the contribution of TRPC3 in Ca2+ entry in PT cells. Compensation of gene expression is often problematic in genetic models; however, PT cells from TRPC3 KO mice did not show any upregulation in expression (as determined by RT-PCR) of other TRPC channels (Fig. S3B), suggesting no alternative candidate in absence of TRPC3 that can be activated by CSR/PLC-operated pathway. Additionally, the major Ca2+ channels in absorptive epithelia, TRPV5 and TRPV6, are also not present in PT cells of TRPC3 KO mice (Fig. S3A,B). To demonstrate the functional compromise in TRPC3 KO mice, we performed Ca2+ imaging to show that both the neomycin (Fig. 6A)- and L-Phe (Fig. 6B)-stimulated Ca2+ entries due to CSR activation were severely attenuated in PT cells of TRPC3 KO mice compared to Ca2+ entries produced in PT cells from WT mice, suggesting that the CSR–TRPC3 interaction contributes to most of the Ca2+ entry into PT cells, and therefore, can be deemed as the major transcellular Ca2+ transport pathway. Since Pyr3 was shown to inhibit other SOCE channels to some extent (Schleifer et al., 2012), we applied Pyr3 on the PT cells from TRPC3 KO mice and observed no leftover Ca2+ entry in those PT cells that could play a substantial role (Fig. 6C). To confirm that the knockdown of TRPC3 results in reduced Ca2+ entry, we examined CSR-activated TRPC3 channel activity by electrophysiology experiments, which is critical for Ca2+ entry and has been used previously as readout for Ca2+ transport in DCT and CD (Goel and...
SCHILLING, 2010). Compared to the WT, the L-Phe-induced current activation was markedly decreased in PT cells from TRPC3 KO mice (Fig. 6D). To determine the contribution of CSR-induced TRPC3 signaling in such current activation, we used NPS-2143 and SKF-96365, which are commonly used to characterize the physiological functions mediated by TRPC channels. Our data show that total current was blocked to a greater extent by either CSR or TRPC inhibitors in WT PT cells compared to in TRPC3 KO PT cells, suggesting the CSR-mediated activation of membrane current is via TRPC3 channel in PT cells (Fig. 6E). Furthermore, to confirm that L-Phe is acting on CSR and specifically activating TRPC3 current by ROCE, we applied Pyr10. Our results show that Pyr10 blocked more L-Phe-induced current (80%) in WT PT cells, compared to a 35% reduction in TRPC3 KO PT cells, providing further evidence that L-Phe induces activation of the CSR–TRPC3-mediated pathway (Fig. 6F). The small block seen in TRPC3 KO PT cells can be attributed to the tendency Pyr10 to also block some SOCE (SCHLEIFER et al., 2012). Finally, to establish the role of TRPC3 in PT Ca\(^{2+}\) transport, we measured lithium clearance (CLi) to probe the in vivo PT Ca\(^{2+}\) reabsorption in TRPC3 KO mice (Fig. 6G). CLi is a marker of Na\(^{+}\), and Ca\(^{2+}\) movement follows that of Na\(^{+}\) in the PT (Garland et al., 1992; Worcester and Coe, 2010). In the absence of Na\(^{+}\) depletion, there is very minimal Li\(^{+}\) reabsorption beyond the LOH. Our purpose here was to test the hypothesis that reduced PT Ca\(^{2+}\) reabsorption in TRPC3 KO mice (as measured by the exogenous CLi) increases Ca\(^{2+}\) delivery to the LOH. Our approach has validity as most of the Ca\(^{2+}\) is reabsorbed in PT and thus CLi will accurately track Ca\(^{2+}\) transport (KRISTIANSEN et al., 1986). Our data show an increase in Li\(^{+}\) in urine of TRPC3 KO mice and thus suggest disruption in PT Ca\(^{2+}\) transport in the absence of TRPC3 (Fig. 6G). Such a difference in enhanced Li\(^{+}\) excretion in KO mice started to display late (after 72 h) and could be due to adaptability to Li\(^{+}\) treatment, which is typical and has been shown for other mice urine measurements such as urine volume, urine osmolarity (Huls et al., 2007) and urine Na\(^{+}\), Ca\(^{2+}\), K\(^{+}\) and Cl\(^{-}\) levels (Sim et al., 2014). The absence of TRPC3 in our animal model was confirmed via further immunofluorescence staining (Fig. S4F). Taken together, these data suggest TRPC3-mediated apical Ca\(^{2+}\) entry in PT cells is a candidate mechanism that can drive the Ca\(^{2+}\) mobilization needed for transcellular Ca\(^{2+}\) transport.
Mice kidney PT cells express functional transcellular Ca\(^{2+}\) flux machinery

Once Ca\(^{2+}\) enters the PT cell, putatively via the apical CSR–TRPC3 complex, resulting in transcellular Ca\(^{2+}\) transport via the Na\(^+\)/Ca\(^{2+}\) exchanger (NCX; isoforms encoded by SLC8A1–SLC8A3) and/or the plasma membrane Ca\(^{2+}\) ATPase (PMCA; isoforms encoded by ATP2B1–ATP2B4), as the major basolateral Ca\(^{2+}\) extrusion proteins (Lambers et al., 2006). Since we found that the CSR–TRPC3 complex contributed to the majority of Ca\(^{2+}\) entry into mice kidney PT cells and can possibly serve as a pathway for transcellular Ca\(^{2+}\) transport, we examined the expression, localization and function of known candidates for the transepithelial Ca\(^{2+}\) transport machinery. To this end, we analyzed Ca\(^{2+}\) transport proteins, which involves Ca\(^{2+}\) shuttling via calbindins and extrusion of [Ca\(^{2+}\)], by NCX and PMCA (Hoenderop et al., 2000). We found transcripts for transport proteins: CaBP9 and CaBP28 (Efcab9 and Calb1, respectively), and NCX1 (Atp2b1), which were found to be specific to the kidney tubules, and PMCA1, which was mainly expressed in PT cells and in the kidneys (Fig. 7A; Fig. S6A,B). Next, we examined the distribution and localization of NCX1 in WT mice kidney sections by immunofluorescence (using megalin as a PT cell marker) and found that NCX1 is mainly localized at the basolateral PM of PT cells (Fig. 7B), whereas PMCA1 was found at both the apical and basolateral side (Fig. 7B). We confirmed PMCA1 localization by staining for sodium bicarbonate exchanger 1 (NBCe1, also known as SLC4A4), another basolateral marker of PT cells (Fig. S6C; Kurt and Zhu, 2013) and NCX1 basolateral localization was in contrast to the apical localization of CSR (Fig. S6D). Having determined

![Fig. 7. Expression, localization and functionality of transcellular pathway machinery in mouse kidney.](image-url)

(A) Transcript levels in WT whole kidney tissue; WT PT cells and TRPC3 KO PT cells were analyzed by RT-PCR and representative gel images were obtained. Gene expression was quantified, normalized to Gapdh and represented as a bar graph. (B,C) Distribution and localization of (B) NCX1 (red; highlighted with white arrows) and (C) PMCA1 (green; highlighted with purple arrows) were determined by immunofluorescence staining using megalin (green; highlighted with yellow arrows) as a PT marker in WT mouse kidney sections. (D) Ca\(^{2+}\) imaging traces of WT PT cells showing L-Phe-induced Ca\(^{2+}\)-flux and the effect of PMCA inhibitor (carboxyeosin; 10 µM) and NCX inhibitor (KB-R7943; 15 µM). Corresponding (E) Ca\(^{2+}\) peak entry, (F) Ca\(^{2+}\) entry rise and (G) Ca\(^{2+}\) entry reduction are represented as bar diagrams. Results represent means ±s.e.m. from n=4 experiments. **P<0.01 (unpaired two-tailed t-test for A and E–G). Scale bars: 20 µm.
expression and distribution of these transport proteins in mice PT cells, we next asked whether these proteins were functionally active. We measured CSR-induced \( \text{Ca}^{2+} \) mobilization in WT PT cells alone, and in cells treated with in the specific PMCA inhibitor carboxyoxolin or the NCX inhibitor KB-R7943 (Balasubramaniam et al., 2017; Jones et al., 2010). Significantly, we observed a greater and prolonged rise in \([\text{Ca}^{2+}]_i\), in the presence of inhibitors compared to control (Fig. 7D), suggesting the lack of extrusion of \( \text{Ca}^{2+} \). We analyzed our data and found that there was a higher peak \( \text{Ca}^{2+} \) rise (Fig. 7E), a higher total \( \text{Ca}^{2+} \) rise (Fig. 7F) and a stagnation of \([\text{Ca}^{2+}]_i\) due to a reduced percentage \( \text{Ca}^{2+} \) clearance (Fig. 7G) in the presence of NCX/PMCA inhibitor than in WT PT cells (Fig. 7D). This indicates that there is a stagnation of \([\text{Ca}^{2+}]_i\), inside the PT cells. Taken together, our results show evidence of expression, distribution and function of intracellular \( \text{Ca}^{2+} \)-handling proteins needed for transcellular \( \text{Ca}^{2+} \) transport in mice PT cells.

**TRPC3 KO mice display predisposing conditions for stone formation**

We quantified urine electrolytes in WT and TRPC3 KO mice to determine how much TRPC3 contributes to \( \text{Ca}^{2+} \) uptake from PT luminal fluid. Our data show that urine \( \text{Ca}^{2+} \)-level is significantly higher in TRPC3 KO mice than in WT mice for a 24 h urine collection, but the serum \( \text{Ca}^{2+} \) level was slightly, but not significantly higher, in TRPC3 KO than in WT mice (Fig. 8A). There were no significant differences in phosphate ion (P), Na, Cl and K in the urine or serum (Fig. 8A) between TRPC3 KO and WT mice ruling out a negative impact stemming from TRPC3 ablation on dysregulation of serum levels of these ions. Moreover, no change was observed in serum PTH levels in TRPC3 KO mice, a possible indication that CSR–TRPC3-induced signaling in the PT is independent of PTH (Loupy et al., 2012). Furthermore, we did not observe any morphological changes by hematoxylin and eosin (H&E) staining in bone tissue of TRPC3 KO mice compared to WT mice (Fig. 8B).

Microscopic analysis of urine samples (24 h collection) from WT and TRPC3 KO mice show the presence of CaP microcrystals, which were much more abundant in the urine of TRPC3 KO mice (Fig. 8C). Those crystals were further quantified and the amount was found to be significantly higher in the urine of TRPC3 KO mice (Fig. 8D), which is considered as a predisposing condition for urinary stone formation (Tisselius, 2011). We did not observe any apparent morphological changes (by H&E staining) in kidney tissue of TRPC3 KO mice compared to WT mice (Fig. 8E), nor were there any significant changes in either urine volume and urine pH between these mice (Fig. 8A,B). It has been proposed that the LOH is the site of initial CaP crystal formation in renal tubule (Evans et al., 2003); therefore, we looked for the presence of CaP crystals that could result from the disruption of movement of \( \text{Ca}^{2+} \) across the PT epithilia through the transcellular route specifically at the LOH region on the ablation of TRPC3. In these studies, we identified microcalcified material by staining with von Kossa (Luna and Gross, 1965) in those kidney tissues from TRPC3 KO mice (Fig. 8F, inset), which is evidence of deposition CaP crystal at the LOH region (Evans et al., 2006). Furthermore, a few spots of microcalcifications were also detected by staining with von Kossa in the calyx region (Fig. 8F inset). These results indicate that TRPC3 KO mice could be prone to calcium stone formations. These crystals were also identified as CaP crystals by Alizarin Red staining, and were not present in kidney tissues in WT mice, but only found in kidney tissues from TRPC3 KO mice (Fig. 8G). The presence of such microcalcifications in kidney tissue of TRPC3 KO mice is similar to what is seen for kidney stones in patients (Khan, 2010). These results warrant further research on the molecular mechanisms underlying the role of PT in kidney stone formation, which can have a clinical and translational impact.

**DISCUSSION**

Here, we show for the first time that there is a PT luminal CSR–TRPC3 complex and demonstrate a possible mechanism to mediate transcellular \([\text{Ca}^{2+}]_o\), mobilization in PT cells, confirming that CSR–TRPC3 signaling can initiate a transcellular \( \text{Ca}^{2+} \) flux into PT cells. Moreover, our findings on the expression, localization and function of epithelial transcellular \( \text{Ca}^{2+} \) flux machinery in \( \text{Ca}^{2+} \) handling strongly support our claim for the existence of a transcellular \( \text{Ca}^{2+} \) transport pathway. \( \text{Ca}^{2+} \) reabsorption in PT cells is described as paracellular; however, it is presently unknown how PT cells handle a sudden rise in PT luminal \([\text{Ca}^{2+}]_o\). In order to prevent CaP crystal formation immediately downstream, at the LOH (Evans et al., 2003), there needs to be an actively regulated \( \text{Ca}^{2+} \) transport pathway that can operate from time to time. Paracellular \( \text{Ca}^{2+} \) flux is a passive process, but our focus was to find an actively regulated transcellular \( \text{Ca}^{2+} \) flux. To this end, we measured \( \text{Ca}^{2+} \) entry via membrane ion channels, which is not a paracellular flux (paracellular flux occurs through tight junctions outside the cell). While we did not investigate the modulation of paracellular flux by our TRPC3–CSR complex due to this spatial discrepancy, it is possible that the rise in \([\text{Ca}^{2+}]_i\), can indirectly modulate paracellular flux, like many other pathways that are regulated by the rise in \([\text{Ca}^{2+}]_o\). We investigated such possibility, as found in the TAL, where it is mediated by claudin-14 (Gong et al., 2012), and examined the expressions of different claudins (i.e. claudin 14, 16 and 19). Our results show that similar to in the TAL, claudin-14 is the major claudin expressed in PT, and the stimulation by \([\text{Ca}^{2+}]_o\) and/or CSR did not change the expression of claudin-14 (Fig. S7C,D). Other possibilities for \([\text{Ca}^{2+}]_o\)-regulated paracellular pathway remain; however, finding those mechanism(s) is beyond the scope of the present manuscript.

In the kidney, different GPCRs, including CSR proteins, are present depending on the functional need of different tubular segments. In the present scenario, luminal expression of CSR in the PT may be highly important, as this receptor can sense the changes in \([\text{Ca}^{2+}]_o\), which could be significant in the regulation of \( \text{Ca}^{2+} \) precipitation. Moreover, in addition to \([\text{Ca}^{2+}]_o\), other modulators, such as protons and amino acids present in PT luminal fluid can activate CSR. Therefore, the physiological variations in plasma amino acid levels are also important to mediate PT cell function, since most of the amino acids are reabsorbed in this segment (Barfuss and Schafer, 1979). We and others have shown that initial \([\text{Ca}^{2+}]_o\), changes (Lee et al., 1997), as well as the \( \text{Ca}^{2+} \) signaling complex formation, occur at the apical region of ion-transporting epithelia (Bandyopadhyay et al., 2005). TRPC3, as a physiological candidate \( \text{Ca}^{2+} \) entry channel is localized at the apical region of PT cells, where CSR is also expressed and triggers such \( \text{Ca}^{2+} \) entry via TRPC3. We demonstrated an obvious role for \([\text{Ca}^{2+}]_o\), in the activation of CSR to signal TRPC3 in PT cells, establishing a PLC-mediated CSR–TRPC3 functional crosstalk. More importantly, we found that pharmacological inhibition of both CSR and TRPC3 diminished the \( \text{Ca}^{2+} \)-entry/transport, which further supports the importance of this complex. Furthermore, our demonstration for the role of PMCA1 and NCX1 strongly supports the idea of transepithelial \( \text{Ca}^{2+} \) transport in PT cells, whereas treatment with the NCX1 inhibitor KB-R7943, presented with a more-pronounced effect on \( \text{Ca}^{2+} \) extrusion. While KB-R7943 also has a blocking effect on TRPC3 (Kraft, 2007), our
data in Fig. 7D show an overall increase and stagnation of \([\text{Ca}^{2+}]_i\) in PT cells when CSR was activated. Furthermore, the distribution of NCX1 compared to TRPC3 is predominantly basolateral in PT cells, which also supports the idea of some selectivity in inhibition of NCX1 by KB-R7943. Finally, the genetic disruption of TRPC3 markedly attenuated \([\text{Ca}^{2+}]_i\) influx in PT cells, and TRPC3 KO mice displayed a phenotype of elevated urinary \([\text{Ca}^{2+}]_i\), microcalcification in the kidney and scattered crystals in the urine, confirming the role of TRPC3 in
microperfusion studies in rats and mice indicate that PT luminal
the absence of any allosteric modulators. In fact, micropuncture and
et al., 2013). Furthermore, the response of the CSR to \([\text{Ca}^{2+}]_o\) could
(Coe et al., 1996). Therefore, our data show that the increase in
both CaP and CaOx, providing the driving force for nephrolithiasis
(Coe et al., 2009). Although, in this study, we specifically aimed to
determine the contribution of CSR-regulated \([\text{Ca}^{2+}]_c\) entry via the
TRPC3 channel, our data show that a decrease in TRPC3 function potentially contributes to the process of CaP crystal nucleation in the
LOH in TRPC3 KO mice. A comparative analysis of the role of
other ions (P, and Ox) with \([\text{Ca}^{2+}]_c\), however, is necessary to determine the
complete picture about the underlying process of CaP/CaOx crystal nucleation. Intriguingly, CSR is also present in the cortical
tubules. However, there it is located mostly at the basolateral membrane
(Ba et al., 2003) and so cannot contribute to apical \([\text{Ca}^{2+}]_c\) entry and is
thus unlikely to play a role in this present mechanism. Moreover,
CaP crystals are formed at the descending LOH, where tubular
fluids are much more concentrated to help in supersaturation.
We propose that the regulation of CSR at PT could prevent urinary calcium stone formation, since this is just upstream to the site of CaP crystal formation. Therefore, this study will enhance our understanding of the regulation of urinary CaP levels, and subsequently CaP and CaP/CaOx mixed stone formation.

The primary physiological function of CSR is to maintain physiological \([\text{Ca}^{2+}]_c\) level within a narrow (1.1–1.3 mM) range
(Brown and MacLeod, 2001). We propose that CSR in the PT luminal membrane can activate a \([\text{Ca}^{2+}]_c\) entry after a rise in PT luminal fluid \([\text{Ca}^{2+}]_l\). The threshold for activation of CSR by \([\text{Ca}^{2+}]_l\) is
1.2 mM and the EC50 is ~1.8 mM (Tharmalingam et al., 2011) in the
absence of any allosteric modulators. In fact, micropuncture and
microperfusion studies in rats and mice indicate that PT luminal fluid \([\text{Ca}^{2+}]_l\) could be sufficient to activate CSR in the PT (Capasso et al., 2013). Furthermore, the response of the CSR to \([\text{Ca}^{2+}]_c\) could be enhanced by modulators that bind to allosteric sites on the CSR and thus require the binding of an orthosteric agonist to the receptor to produce their effects, where a nominal change can produce a downstream effect (Conigrave and Lok, 2004). We have demonstrated the activation of CSR by endogenous modulators, such as L-Phe and L-Try, in the salivary duct (Bandyopadhyay et al., 2012), and that such activation of CSR in PT is possible as this is an active site for transport of those amino acids (Bröer, 2008). Thus, CSR signaling is relevant to both normal and elevated \([\text{Ca}^{2+}]_c\) in PT luminal fluid. The modulation of CSR activity by L-Phe/L-Try could have a physiological role in the PT (Kragh-Hansen et al., 1984), similar to in the gastrointestinal tract (Busque et al., 2005).

In addition, charged peptides in the PT luminal fluid may contribute to the sensitization of CSR by decreasing its EC50 (Quinn et al., 1997; Walter et al., 2013), the scope of testing those additional modulators could be generated in our future studies.

Besides the increase in \([\text{Ca}^{2+}]_c\), the ambient pH has a profound effect on the supersaturation of \([\text{Ca}^{2+}]_c\) and phosphate necessary for the formation CaP, and the crystallization of CaP is strongly favored by a pH of 6.5 or greater (Berg and Tiselius, 1986). The solubility of CaP crystals is also pH dependent and is greatly increased at a pH of 6.2 or less. An incomplete form of PT acidosis has been described in patients with hypercalcuria and stone disease, characterized by abnormal bicarbonaturia (Mateos Antón et al., 1984). In these patients, it is speculated that transient bicarbonaturia, especially if other risk factors such as hypercalcuria are present, promotes favorable conditions for the formation of a CaP nidus, possibly in the tip of the LOH, where luminal pH normally increases to 7.30 from 7.06 in the early PT (Brenner et al., 2008). It is also possible that other pH determinants such as HCO3− and citrate could affect such CaP crystal formation (Buckalew, 1989). We propose that CaP crystal deposition in LOH could be the predisposing factor for CaP crystal formation, which increases rapidly as tubular pH rises from 6.0 to 7.0. Since CaOx stones can form over an initial CaP layer (Evans et al., 2003), such an intervention strategy should lower the supersaturation of both species. Therefore, our results can initiate future preclinical and translational studies along these lines, invoking urinary acidification/alkalization in PT-specific mice models to determine the role of CaP in CaP+CaOx mixed stone formation. Since the majority of kidney stones are found to be CaOx (Parks et al., 2004), the research conducted over the past three to four decades has largely been focused on delineating the mechanism of CaOx stone formation (Pearle et al., 2005). Interestingly, there has been a documented increase in the prevalence of pure CaP kidney stones over the past two decades (Parks et al., 2009), which suggests an epidemiological shift and thus signifies a greater demand for focused research into such CaP stone formation.

MATERIALS AND METHODS

Animals

TRPC3 KO mice (−/−) were generated by disrupting the Trpc3 gene as previously reported (Hartmann et al., 2008). The animal protocols of this study was designed according to the Guiding Principles in the Care and Use of Animals, and approved by the Institutional Animal Care and Use Committee and the Research and Development Committee of DC Veterans Affair Medical Center. Adult WT and TRPC3 KO mice (weighing 25–35 g), both males and females, were kept under environmentally controlled conditions (12 h light–12 h dark cycle, 20–22°C) with food and water being made available ad libitum until used. The mice were treated in accordance with the NIH Animal Care and Use guidelines.

Reagents and chemicals

Pyr3, NPS-2143, SKF-96365, U-73122 and U-73342 were purchased from Tocris Bioscience (Minneapolis, MN). L-Phe, L-Try, neomycin, EGTA, OAG, Pyr6, Pyr10, angiotensin II (an angiotensin receptor agonist), KB-R7943 and losartan potassium (angiotensin type 1 receptor blocker), were purchased from Sigma-Aldrich (St Louis, MO). Fura-2-acetoxymethyl ester (Fura-2-AM) and Fluo-4-acetoxymethyl ester (Fluo-4-AM) were purchased from Invitrogen (Carlsbad, CA). Carboxyoxin was purchased from Marker Gene Technologies (Eugene, OR). All the chemicals used were analytical grade. Anti-TRPC3 antibody was produced (rabbit polyclonal) as previously described (Bandyopadhyay et al., 2005). Antibodies against the following proteins were used for immunoblotting (IB) and immunofluorescence (IF): PMCA (mouse; Novus Biologicals, Centennial, CO; cat. #NB300-578); zonula occludens (ZO1, also known as...
MgCl2, 10 mM Na-HEPES, 10 mM glucose; pH 7.4) with 0.02% soybean extracellular saline (SES) buffer (145 mM NaCl, 5 mM KCl, 1 mM eutanasia of the mice, and then washed in an ice-cold standard mice and WT littermates using published techniques with some Millipore, Burlington, MA) for 2
For primary culture, these cells were placed onto Transwell filters (EMD Proteintech, Rosemont, IL; Cat #11885-1-AP).

Cell culture, isolation and primary culture of PT cells Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), antibiotics (penicillin and streptomycin) and glutamine were purchased from Invitrogen. The porcine renal proximal tubule cell line LLC-PK1 (confirmed as contamination negative on 7 October 2018), was purchased from ATCC (Manassas, VA). LLC-PK1 cells were cultured in DMEM, supplemented with 10% FBS, 2 mM glutamine, 1% penicillin and streptomycin at 37°C in 5% CO2. Renal PT cells were isolated and cultured from kidneys of TRPC3 KO mice and WT littermates using published techniques with some modifications (Bandyopadhyay et al., 2005, 2012; Kamiyama et al., 2012; Zhao et al., 2011). Briefly, kidneys were removed immediately after euthanasia of the mice, and then washed in an ice-cold standard extracellular saline (SES) buffer (145 mM NaCl, 1 mM MgCl2, 10 mM Na-HEPES, 10 mM glucose; pH 7.4) with 0.02% soybean trypsin inhibitor and 0.1% bovine serum albumin (BSA). Thereafter, the kidney was decapsulated, bisected and sliced in coronal sections. Cortical tissues from the kidneys were used to isolate PT cells by enzymatic digestion (1% Worthington collagenase Type II and 0.25% soybean trypsin inhibitor, Worthington Biochemical Company, Freehold, NJ). The cell suspensions were passed through a series of mesh filters, and then resuspended in 45% Percoll gradient for centrifugation at ~27,000 g for 15 min at 4°C. PT cells, which sediment to a layer immediately above the erythrocyte pellet, were centrifuged and washed to remove the remaining Percoll, and resuspended in SES medium (for immediate use, or for culture DMEM containing antibiotics and growth factors). PT cells were cultured as described previously (Chung et al., 1982). The basal culture medium used is DMEM containing 10% FBS, supplemented with 2 mmol/l glucose, 100 IU/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml insulin, 5×108 mol/l hydrocortisone, 5 µg/ml transferring, 2 mmol/l butyrate, 2 mmol/l alanine and 2 mmol/l lactate. The bicarbonate concentration was adjusted to 24 mmol/l to maintain the medium at pH 7.4 to 7.5. We used freshly dispersed cell preparations, which contain single cells, fragmented tubular structures of PT cells, or intact PT structures that can thus can be loaded with Ca2+ dye indicator for use in the Ca2+ imaging experiments. For primary culture, these cells were placed onto Transwell filters (EMD Millipore, Burlington, MA) for 2–3 days until they achieve confluence. We also used single-cell preparations for all electrophysiology experiments.

RNA extraction and RT-PCR The mRNA was detected by semi quantitative RT-PCR. Briefly, total RNAs from PT cells were isolated using TRIzol as previously described (Yiu et al., 2017). Thereafter, samples were processed through DNase treatments and subsequently RNA concentrations were measured by using a nanodrop spectrophotometer. A cDNA synthesis kit (Promega, Madison, WI) was used to reverse transcribe the RNA into the cDNA, which were then amplified by using gene-specific primers (Table S1) purchased from Invitrogen and Integrated DNA Technologies (Corvalle, IA) using a master mix PCR amplification reagent kit (Promega). Amplifications were performed using a T100 Thermocycler (Bio-Rad, Hercules, CA), the following PCR conditions were used: one initial cycle at 95°C for 3 min; 30–35 cycles of denaturation at 95°C for 30 s, annealing at 35°C for 30 s, and elongation at 72°C for 45 s; an additional 5 min at 72°C; and a final hold at 4°C. The DNA samples were loaded onto a 1% agarose gel containing 0.5 µg/ml ethidium bromide and were run with 0.5× TBE running buffer. The DNA was visualized by a UV transilluminator, and the images were captured with a camera system (Fluor Chem TM 8800; Alpha Innotech, San Leandro, CA). GAPDH was used as an internal control. The PCR products intensities were determined by densitometric analysis using ImageJ software (NIH).

Immunocytochemistry of kidney sections Mice tissue sections (~5–7 µm) were prepared from whole kidney collected from the mice after euthanasia, which were immediately fixed in 10% formalin solution for 24 h and then dehydrated in graded concentrations of ethanol and embedded in paraffin. Immunohistochemistry was performed on paraffin sections of mice kidneys, as described previously (Bandyopadhay et al., 2005). Sections were stained with anti-CSR antibody, H&E stain or Alizarin Red stain as described previously (Thompson et al., 2008).

Immunofluorescence and confocal imaging cells To determine the location of TRPC3 and ZO1 in LLC-PK1 cells, polarized monolayers of cells were grown in 12 or 24-mm Transwell filters in DMEM with 10% FBS, and establishment of polarized epithelia was confirmed as described previously (Bandyopadhay et al., 2012). All steps were performed at room temperature, unless otherwise specified and as described earlier (Bandyopadhay et al., 2012). Briefly, cells were rinsed with 1× PBS, and then fixed with 3% paraformaldehyde in PBS, pH 7.4 for 30 min. Then, the cells were rinsed again with PBS, and treated with 100 µM of glycine in PBS for 20 min. The cells were then washed and permeabilized with methanol (80%)+DMSO (20%) at ~20°C for 5 min. Following incubation with a blocking solution containing 5% donkey serum and 0.5% BSA in PBS (PBS-BSA) for 20 min, the cells were incubated with primary antibodies for 1 h at room temperature, washed with PBS-BSA, and probed with the required FITC- or Rhodamine-conjugated secondary antibody (Jackson Immuno Research, West Grove, PA). The filter (containing the cells) was excised and mounted onto a slide with anti-fade reagent (Ted Pella, CA) to detect expression. Fluorescence images were obtained using a confocal laser scanning microscope Leica TCS-SP2 attached to an upright Leica DM-RE7 microscope.

Tissue sections Sections of kidneys were prepared as described previously (Bandyopadhay et al., 2012) after fixation and permeabilization, which were then rehydrated, blocked, and incubated with rabbit (anti-TRPC3, anti-Megalin, anti-NBCe1a, and anti-CSR, all at 1:200) and mouse (anti-CSR, anti-NCX, anti-PMCA, and anti-Na+/K+-ATPase, all at 1:100) antibodies overnight at 4°C. In colocalization experiments anti-CSR antibody (1:100 dilution) was used with anti-TRPC3 antibody (Bandyopadhay et al., 2005, 2012). Appropriate controls for anti-TRPC3 and -CSR antibodies were used instead of the primary antibodies, which did not result any positive staining. To determine the colocalization between the rabbit and mouse antibodies, the sections were probed using different secondary antibodies at 1:100 dilutions [Alexa-Fluor 488-conjugated donkey anti-rabbit IgG or anti-mouse IgG (for rabbit or mouse primary antibodies, respectively) and Alexa-568 donkey anti-rabbit IgG or anti-mouse IgG (for rabbit or mouse antibodies, respectively)] for 30 min. Images were visualized using Zeiss 710 confocal microscopes and further analyzed using Zeiss software (Zen 2010). In our labeling controls (for background subtraction), isotypes were used instead of the primary antibodies and then the secondary antibodies (Alexa Fluor 488 and/or 568-conjugated secondary antibody; Thermo Fisher Scientific) were added.

Immunoblotting For LLC-PK1 cells, cells were harvested by adding ice-cold PBS containing 1% (v/v) aprotinin (Sigma-Aldrich), and immediately solubilized by adding RIPA buffer containing protease inhibitors, as described previously (Liu et al., 2005). For mice kidney tissue, proteins were isolated from renal cortex and medulla sections as described previously (Bandyopadhay et al., 2012). Protein concentration was quantified using the BioRad protein assay. Proteins were detected by western blotting using mouse anti-CSR (1:400 dilution), anti-Na+/K+-ATPase (1:1000) and anti-TRPC3 (1:500) primary antibodies, the required secondary antibody, and treatment with enhanced chemiluminescence (ECL, Thermo Fisher, catalog # 34095) reagent as described previously (Liu et al., 2005).

Immunoprecipitation and cell surface biotinylation PT cells, grown in Transwell filters, with serum-free DMEM (24 h), were washed once by adding ice-cold phosphate-buffered saline (PBS)
were visualized with anti-TRPC3 (1:500) and anti-Na+/K+-ATPase (1:1000) antibodies, followed by addition of protein A–Sepharose beads. Protein-bound beads were separated by a brief centrifugation. The supernatant was extracted and saved (unbound fraction). The beads were washed and bound proteins (IP-fraction) were eluted by boiling in SDS-PAGE sample buffer for 5 min and then separated by SDS-PAGE. Proteins were semi-quantified by western blotting, as described previously (Bandypadhyay et al., 2005, 2008).

Immunocomplexes were pulled down by adding anti-TRPC3 (1:100) and anti-CSR (1:100) antibodies, followed by addition of protein A–Sepharose beads. Protein-bound beads were separated by a brief centrifugation. The supernatant was extracted and saved (unbound fraction). The beads were washed and bound proteins (IP-fraction) were eluted by boiling in SDS-PAGE sample buffer for 5 min and then separated by SDS-PAGE. Proteins were semi-quantified by western blotting, as described previously (Bandypadhyay et al., 2005, 2008), using anti-TRPC3 (1:500) and anti-CSR (1:400) primary antibodies, the required secondary antibody, and treatment with ECL reagent. PT cells were incubated for 1 min, 3 min and 5 min with or without L-Phe (100 μM) at 37°C in 0.5 mM Ca2+–containing serum medium, then washed, and re-incubated for another 20 min with 0.5 mg/ml Sulfo-NHS-Biotin (Pierce) on ice. The cells were washed with buffer containing 0.1 M glycine and solubilized with 2 ml of RIPA buffer.

Biotinylated proteins were pulled down with neutravidin-linked beads. Protein-bound beads were separated by a brief centrifugation. The supernatant was extracted and saved (unbound fraction). The beads were washed and bound proteins (IP-fraction) were eluted by boiling in SDS-PAGE sample buffer and analyzed by western blotting. The proteins were visualized with anti-TRPC3 (1:500) and anti-Na+/K+ ATPase (1:1000) antibodies. The details of these methods were described previously (Bandypadhyay et al., 2008). To determine the compartmentalized (apical versus basolateral) association of CSR and TRPC3 using co-IP, purified basolateral and apical membranes were collected from PT cells from WT mice for co-IP assays (Mazzone et al., 2006).

**Measurements of compartmentalized apical and basal [Ca2+] mobilization in polarized PT cells**

Cells were grown on Transwell filters and the transepithelial electrical resistance (TER) was measured to confirm the establishment of polarization, as previously described (Bandypadhyay et al., 2005). Integrity of the monolayers and the tight junctions were determined by serial measurement of TERs at ~130 Ω cm2 across cell monolayers to ensure the polarity. Thereafter, the cells were incubated with 5 μM Fura-2-AM at 37°C for 1 h in serum medium. After the Transwell inserts were washed, 2 ml SES medium were added in the apical chamber and the inserts were placed in 35 mm chambers containing 2.5 ml SES medium in the basal chamber. All drugs were added in the apical chamber. The samples were scanned in xz-time mode by confocal (Zeiss 710) microscopy for 5 min total time with 12 s increments between sampling. The calculations of the mean intensity in a defined region of interest (ROI) were made using the histogram function of the Zen 2010 image analysis software, analyzing whole cell, basal and apical regions throughout the time series as previously described (Bandypadhyay et al., 2005, 2012).

**[Ca2+] measurements by time-lapse fluorescence (ratiometric method)**

[Ca2+] measurements were performed by ratiometric (340:380 nm) method as previously described (Bandypadhyay et al., 2012; Yu et al., 2017). Fura-2-loaded cells were placed on an IX81 motorized inverted microscope equipped with an IX2-UCB control box (Olympus USA, Center Valley, PA). All experiments were conducted in a humidified incubator with a constant temperature set at 37°C and a gas mixture of 95% air and 5% CO2. For time-lapse fluorescence ratiometric measurements, the IX81 microscope images were fed into a C9100-02 electron multiplier CCD camera, equipped with a monochromator (Hamamatsu, Bridgewater, NJ). A Lambda-LS xenon arc lamp and 10-2 optical filter changer (Sutter Inst. Novato, CA) were used as an illuminator capable of light output from 340 and 380 nm to a cutoff of 700 nm. Ratiometric measurements of [Ca2+] were obtained using digital microscopy imaging software (SlideBook version 5.0, 3i, Intelligent Imaging Innovations, Denver, CO). Fura-2 fluorescence was recorded at an emission peak absorbance of 500 nm wavelength with excitation peak absorbance that continuously shifted between wavelengths of 340 nm and 380 nm. The cells were brought into focus using a differential interference contrast channel. Time-lapse recordings were set different time points according to the experimental protocols (200–700 s), with images taken at 1 s intervals, and measured an average of 50–150 cells for a selection of ROIs (background fluorescence automatically subtracted prior to 340/380 ratio calculation and graphing). Analysis was performed offline using Slidebook™ software and further analyzed using statistical analysis by Origin 6.1. All other details are stated in Figure legends.

**Electrophysiology**

The whole-cell patch clamp technique was employed to measure ion currents from single cells as described previously (Bandypadhyay et al., 2011, 2017). The cells were bathed in an external solution containing (in mM): 140 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 5 D-glucose and 10 HEPES (NaOH, pH 7.4). The intracellular solution contained (in mM): 50 CsCl, 10 NaCl, 60 CsF, 20 EGTA, and 10 HEPES (CsOH, pH 7.2). Whole-cell recordings were obtained with an EPC-10 digitally controlled amplifier and Patchmaster software (HEKA, Lambrecht, Germany). I–V relationships were measured every 3 s by applying voltage ramps (300 ms) from −100 mV to +100 mV from a holding potential of −80 mV. Data were acquired at 5.00 kHz and filtered at 2.873 kHz. After establishing the whole-cell configuration, the membrane resistance was >500 MΩ. All experiments were performed at a constant room temperature set at 25°C.

**Mice urine electrolyte and pH measurements**

Mice were individually housed in metabolic cages (Nalgene, Rochester, NY) with free access to food and water. Spontaneously voided urine (24 h) was collected daily under mineral oil after a 6-7 days acclimation period, which continued for 7 additional days for determination of electrolyte excretion (Bandyopadhyay et al., 2009). Urine pH was measured immediately after collection using Orion Star A121 portable pH meter (Thermo Fisher Scientific). The amount of urine and serum electrolytes, such as Ca2+, Na+, K+, Cl−, and L−, were measured using a Medica EasyLyte Analyzer (Bedford, MA). Urine and serum phosphate levels were measured using a QuantiChrom™ Phosphate Assay Kit (BioAssay Systems). Urine and serum Ca2+ measurements were confirmed by using a Random Calcium Assay Kit (Randox Laboratories; cat. #CA2390). Serum PTH was measured using a human PTH EIA kit (RayBiotech Life, Nocrocross, GA).

**Mice urine crystal staining and quantification**

Urine crystals were stained using Alizarin Red 4.3 to specifically identify The CaP crystal (Thompson et al., 2008). The area of crystals was quantified using ImageJ software as previously described (Lau et al., 2017) and the statistical analysis was performed using Origin 6.1.

**Urinary Li-clearance measurement**

We examined the in vivo PT Ca2+ transport by measuring Cl− and Na+ excretion at different time intervals after supplementation of 2 mmol/kg LiCl in the drinking water of WT and TRPC3 KO mice for 24 h. Thereafter, urine and blood (for serum) were collected to measure Ca2+, Na+ and L− levels with a Medica EasyLyte Analyzer (Bedford, MA).

**Statistical analysis**

Experimental data were plotted, and the curve-fitting was performed using Origin 6.1 and PSPPP. The data are expressed as means±s.e.m. Statistical comparisons were performed using a Student’s unpaired t-test (two-tailed), or one-way ANOVA and post-hoc Tukey for multi-group comparison, as appropriate, in Origin 6.1. Tukey’s test was performed using GNU PSPP Statistical Analysis Software (Free Software Foundation, Boston, MA, USA). Statistically significant comparisons were accepted at P<0.05.

**Acknowledgements**

We acknowledge the technical help of Maryam Al-Shatti, Razia Sultana in Ca2+-imaging experiments, and Drs Sanjit K. Roy and Bok-Eum Choi for RT-PCR experiments. Our special thanks to Samuel Shin, Eugenia Awhah Boadi and


**Fig. S1. Expression of maker genes and functional test for cultured PT cells.** Marker genes expression (mRNA) profile of WT mice (A) isolated and cultured mice PT cells and (B) whole kidney tissue (control) were determined using published gene specific primers. Details of RT-PCR primers are described in Table S1. The mRNA was detected by semi quantitative RT-PCR. The PCR products examined onto a 1% agarose gel stained with ethidium bromide. kb: kilo base pair (bp).

(C) Mean fluorescence traces of fura-2-loaded PT cells stimulated with an Angiotensin receptor agonist, Angiotensin II (ANG II; 10^{-7} M), and then exposed to 2 mM Ca^{2+} to induce Ca^{2+} entry in PT cells (black trace), which was blocked (red trace) by 10 μM losartan (angiotensin receptor inhibitor). (D) This functional test in C. was confirmed via whole-cell patch clamp. Unpaired two-tailed t-test: *, p < 0.05; **, p < 0.01.
Fig. S2. Localization of CSR in Mice PT. Immunocytochemical (A) and Immunofluorescence (B) staining of WT mice kidney section (cortical view) using specific primary antibody to CSR (details are in the Methods section). (A) Strong apical CSR brown (diaminobenzene) signals (indicated by blue arrows) in the PT brush border membrane. (B) CSR was co-stained with anti-\(\text{Na}^+\text{-K}^+\text{-ATPase}\) antibody using Alexa Fluor 488 (green signals) and Alexa Fluor 568 (red signals) secondary antibodies respectively to demonstrate the presence CSR in PST and PCT. This also confirm the CSR signals (red/green) specificity compared to the Fig 2C. Scale bars: 10 µm.
**Fig. S3. Expression of TRPC genes in PT cells.** Expression profile of TRPC genes in (A) WT and (B) TRPC3 KO mice PT cells was determined using gene-specific primers ([Table S1](#)), which shows that there is no change in other TRPC gene expression in TRPC3 KO mice PT cells. Whole Kidney (C) was used as control. The mRNA was detected by semiquantitative RT-PCR. The PCR products shown were detected in 1% agarose gel stained with ethidium bromide. Expressions of GAPDH was used as an internal control.
Fig. S4. Confirmation of TRPC3 antibody and analysis of TRPC3 KO mice. Immunofluorescence staining of TRPC3 (green) and Na\(^+\)-K\(^+\)-ATPase (red) in WT mice kidney section (A) showing cortical view and (B) strong signal in PT brush border with white arrows. Images in (C-D) depict the apical expression of TRPC3 as a result of staining with TRPC3 antibody (green signals) and Na\(^+\)-K\(^+\)-ATPase (red) was used as a basolateral maker (WT mice kidney section); (C) shows the brush border of proximal convoluted tubule (PCT) with white dotted shape and (D) indicates strong apical TRPC3 signal at the brush border membrane of proximal straight tubule (PST; white dotted shape). Immunofluorescence of paraffin-embedded kidney tissue sections from (E) TRPC3 WT and (F) KO mice stained with anti-TRPC3 antibody showed strong apical signals on WT section (white arrows); whereas anti-TRPC3 antibody staining to TRPC3 KO kidney section shows the absence of detectable green signals. (G) Anti-Rabbit secondary (2\(^{\circ}\)) antibody (Alexa Fluor 488), which were used for staining TRPC3 primary antibody (Figure 3B), was stained as negative control in WT section. DIC overlays were used (E-G) for demarcation purpose. (H) Anti-CSR antibody on a serial section shows strong apical red signals. Na\(^+\)-K\(^+\)-ATPase (green) was used as a basolateral maker. Scale bars: 20 µm
Fig. S5. CSR activation supports persistent \( \text{Ca}^{2+} \)-entry and CSR-TRPC3 forms apical \( \text{Ca}^{2+} \) signaling complex, modulated by TRPC3 surface expression. (A) Mean fluorescence traces of fura-2-loaded PT cells stimulated with 10 mM L-Phe in presence of 0.5 mM \( \text{Ca}^{2+} \), and then exposed to 5 mM \( \text{Ca}^{2+} \) to induce persistent \( \text{Ca}^{2+} \)-entry in PT cells, which was rapidly blocked by 10 mM EGTA. Values are plotted (n = 4) as the means ± s.e.m. Apical (AP) and basolateral (BL) membranes were isolated from kidney cortical tissue from rats. Immunocomplexes were pulled down to show proof of concept of TRPC3 interaction with CSR at the apical membrane via co-IP and IB (B) AP and BL pre-IP (input) and IP with CSR and IB TRPC3 shows formation of apical complex only; (C) IP with CSR and IB with CSR antibody used as a control where apical complex is very prominent. (D-E) Biotinylated protein lysates from PT cells were immunoprecipitated with NeutrAvidin beads. IB shows (D) 1 minute and (E) 5 minutes stimulation of CSR with \( \text{Ca}^{2+} \) (2 mM) plus L-Phe (10 mM) in PT cells which induced an increase in TRPC3+CSR complexes (compared to unstimulated control). Bands were quantified and represented as bar diagram. (F) Line graph represents TRPC3 PM expression after 1, 3, and 5-minutes exposure after stimulation with \( \text{Ca}^{2+} \) or \( \text{Ca}^{2+} \) plus L-Phe. Results represent means ± s.e.m from n = 3 experiments. Unpaired two-tailed t-test: *, p < 0.05; **, p < 0.01.
Fig. S6. Expression and localization of PMCA and NCX in WT PT. (A) Expression profile of PMCA genes in WT mice PT cells was determined using gene-specific primers (Table S1), which shows prominent expression level of PMCA1 (Bar diagram). The mRNA from PT cells was detected by semiquantitative RT-PCR. The PCR products shown were detected in 1% agarose gel stained with ethidium bromide. Megalin was used as PT cells control. PMCA1 expressed both apical and basolateral membrane (B); DIC + PMCA1 (green signals). (C) Co-staining of PMCA1 and NBCe1 (basolateral PT marker). (D) Co-staining of NCX1 with CSR showing basolateral localization of NCX1. Yellow arrows indicate apical. White arrows indicate basolateral. One-way ANOVA and Tukey test (A): *, p < 0.05; **, p < 0.01. Scale bars = 20 µm.
Fig. S7. Urine properties of WT and TRPC3 KO mice and expression of Claudins in PT cells. WT (black bars) and TRPC3 knock out (red bars) mice (A) Urine volume and (B) pH were immediately measured after 24 hours urine collection. (C) Basal mRNA expression levels of tight junction proteins Claudin-14, 16, 19 (megalin was used as PT cells control) in WT PT cells. (D) mRNA expression levels of Claudin-14 following stimulation of WT PT cells with Ca$^{2+}$ 2mM; Ca$^{2+}$ 2mM + 2mM L-Phe for 24 h (n=3). The mRNA was detected by semiquantitative RT-PCR. The PCR products shown were detected in 1% agarose gel stained with ethidium bromide. Bar diagram values represent means ± s.e.m. Unpaired two-tailed t-test (A, B, and D); one-way ANOVA and post-hoc Tukey test (C); *, p < 0.05; **, p < 0.01.
Table S1. Primers used to amplify mRNAs encoding mouse genes based on published GenBank sequences for mice. Respective expected PCR product sizes for each primer are also provided. Abbreviations: TRPC = transient receptor potential channel canonical; TRPV = transient receptor potential channel vanilloid; PMCA = plasma membrane Ca\(^{2+}\) ATPase; NCX = sodium calcium exchanger; CaBP = calbindin protein; SMA = smooth muscle actin; Ae = anion exchanger; Aqp = aquaporin; CLDN = Claudin.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (sense, antisense)</th>
<th>Product Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mGAPDH</td>
<td>5'-TGAGGACACACCGTGTCTCTCT-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>303</td>
</tr>
<tr>
<td>mTRPC1</td>
<td>5'-CAAGATTTGGGAAATTTCTTG-3' 5'-TTTATCTCTGATTTGCTAT-3'</td>
<td>371</td>
</tr>
<tr>
<td>mTRPC2</td>
<td>5'-GAACGCTCTCTTGAGG-3' 5'-GACAGGAGCAAACTCGACT-3'</td>
<td>327</td>
</tr>
<tr>
<td>mTRPC3</td>
<td>5'-TGACTCCGGTTGAGTC-3' 5'-CCTTCTGAAGCCTTCGCT-3'</td>
<td>317</td>
</tr>
<tr>
<td>mTRPC4</td>
<td>5't CGGATTTTGGGAAATTTCTTG-3' 5'-TTTATCCTCATGATTTGCTAT-3'</td>
<td>326</td>
</tr>
<tr>
<td>mTRPC5</td>
<td>5'-TCTCGGACACCGTGTCTCTCTC-3' 5'-GAGCGTCACGTCCTGTAGTGC-3'</td>
<td>427</td>
</tr>
<tr>
<td>mTRPC6</td>
<td>5'-GATGCTCTCCGGTTGAGG-3' 5'-GAGCGTCACGTCCTGTAGTGC-3'</td>
<td>499</td>
</tr>
<tr>
<td>mTRPC7</td>
<td>5'-GAGCGTCACGTCCTGTAGTGC-3' 5'-TCTCGGACACCGTGTCTCTC-3'</td>
<td>169</td>
</tr>
<tr>
<td>mTRPV5</td>
<td>5'-TTTGGGGAGAACCACAGCCTCAAACACACACCAGAGGCTCTA-3'</td>
<td>318</td>
</tr>
<tr>
<td>mTRPV6</td>
<td>5'-AACCGCCCTTCTCCACACCACACCAGAGGCTCTA-3' 5'-TCTCGGACACCGTGTCTCTC-3'</td>
<td>523</td>
</tr>
<tr>
<td>mPMCA1</td>
<td>5'-TGAGGACACACCGTGTCTCTCT-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>427</td>
</tr>
<tr>
<td>mPMCA2</td>
<td>5'-TGAGGACACACCGTGTCTCTCTC-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>392</td>
</tr>
<tr>
<td>mPMCA3</td>
<td>5'-TCTCGGACACCGTGTCTCTC-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>563</td>
</tr>
<tr>
<td>mPMCA4</td>
<td>5'-TCTCGGACACCGTGTCTCTC-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>487</td>
</tr>
<tr>
<td>mNCX1</td>
<td>5'-GCCATCCTCCAGGTTGAG-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>326</td>
</tr>
<tr>
<td>mCaBP9</td>
<td>5'-GCCATCCTCCAGGTTGAG-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>326</td>
</tr>
<tr>
<td>mCaBP28</td>
<td>5'-GCCATCCTCCAGGTTGAG-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>326</td>
</tr>
<tr>
<td>mSMAC</td>
<td>5'-GCCATCCTCCAGGTTGAG-3' 5'-GCCCTCTCCTTGATTATGGG-3'</td>
<td>326</td>
</tr>
<tr>
<td>mCD13B</td>
<td>5'-TCAAGGAGCTTGGGAAATTTCTTG-3' 5'-TTTATCTCTGATTTGCTAT-3'</td>
<td>798</td>
</tr>
<tr>
<td>mCLDN14</td>
<td>5'-ACCTGGTTGAGTGAACCTACAG-3' 5'-TTTATCTCTGATTTGCTAT-3'</td>
<td>131</td>
</tr>
<tr>
<td>mCLDN16</td>
<td>5'-ACCTGGTTGAGTGAACCTACAG-3' 5'-TTTATCTCTGATTTGCTAT-3'</td>
<td>179</td>
</tr>
<tr>
<td>mCLDN19</td>
<td>5'-ACCTGGTTGAGTGAACCTACAG-3' 5'-TTTATCTCTGATTTGCTAT-3'</td>
<td>187</td>
</tr>
</tbody>
</table>